Global Medulloblastoma API Manufacturers, Marketed and Phase III Drugs Landscape, 2017 - Research and Markets
February 17 2017 - 10:15AM
Business Wire
Research and Markets has announced the addition of the
"Medulloblastoma - Global API Manufacturers, Marketed and Phase III
Drugs Landscape, 2017" drug pipelines to their offering.
Medulloblastoma - Global API Manufacturers, Marketed and Phase
III Drugs Landscape, 2017, provides comprehensive insights about
the marketed drugs, drug sales, Phase III pipeline drugs and their
API Manufacturers across the globe.
A key objective of the Medulloblastoma Report is to understand
the market and pipeline status of the drugs around the
Medulloblastoma to explore the generic development opportunities,
licensing opportunities and to gain competitive advantage on
designing pipeline strategies. The Report provides the historical
and forecasted sales of the drugs till 2018.
The Medulloblastoma Report gives insights into patents providing
the patent protection data and marketing exclusivity of all the
drugs across the Medulloblastoma.
While the leading brands, companies and chemicals are considered
thoroughly, the report also provides details on the Global API
Manufacturers across the globe covering Drug Master Filings of US,
Europe and API Manufacturers in Asia specifically China and
India.
Key Topics Covered:
1. Indication Overview
2. Market Drugs Landscape
3. Global API Manufacturers Assessment
4. Phase III Drugs Landscape
5. Drugs Market Data and Forecasted Sales Figure-2018
6. Marketed Drugs for Medulloblastoma
7. Phase III Drugs for Medulloblastoma
8. Discontinued Drugs for Medulloblastoma
9. Appendix
For more information about this drug pipelines report visit
http://www.researchandmarkets.com/research/lxjh8r/medulloblastoma
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170217005517/en/
Research and MarketsLaura Wood, Senior
Managerpress@researchandmarkets.comFor E.S.T Office Hours Call
1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT
Office Hours Call +353-1-416-8900U.S. Fax: 646-607-1907Fax (outside
U.S.): +353-1-481-1716Related Topics: Brain Cancer Drugs